BNRNasdaqServices-Medical Laboratories
Burning Rock Biotech Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 28, 2026
$12.29−0.61 (-4.73%)
Close on Oct 19, 2026
Share price
+$4.25 (+52.86%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Burning Rock Biotech Ltd grew revenue 4.6% to CN¥539.57M over fiscal 2025. Free cash flow was -CN¥33.69M.
Revenue
CN¥539.57M
+4.6% vs. a year earlier
Operating income
-CN¥54.85M
FY2025
Free cash flow
-CN¥33.69M
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- CN¥539.57M
- Net income
- -CN¥55.35M
- Free cash flow
- -CN¥33.69M
Valuation needs the share price. It fills in once daily prices are connected and converted from CNY.
Nine years at a glance
Fiscal years 2017 to 2025, CNY
Revenue
CN¥539.57M+4.6% YoY
Gross profit
CN¥402.91M+11.2% YoY
Operating income
-CN¥54.85M
Net income
-CN¥55.35M
EPS, diluted
–
Free cash flow
-CN¥33.69M
Reported period